Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes
- Author(s)
- Brunner, AM; Esteve, J; Porkka, K; Knapper, S; Traer, E; Scholl, S; Garcia-Manero, G; Vey, N; Wermke, M; Janssen, Jjwm; Narayan, R; Fleming, S; Loo, S; Tovar, N; Kontro, M; Ottmann, OG; Naidu, P; Sun, H; Han, M; White, R; Zhang, N; Mohammed, A; Sabatos-Peyton, CA; Steensma, DP; Rinne, ML; Borate, UM; Wei, AH;
- Details
- Publication Year 2024-11-22,Volume 99,Issue #2,Page E32-E36
- Journal Title
- American Journal of Hematology
- Abstract
- The safety and efficacy of sabatolimab, a novel immunotherapy targeting T-cell immunoglobulin domain and mucin domain-3 (TIM-3), was assessed in combination with hypomethylating agents (HMAs) in patients with HMA-naive revised International Prognostic System Score (IPSS-R) high- or very high-risk myelodysplastic syndromes (HR/vHR-MDS) or chronic myelomonocytic leukemia (CMML). Sabatolimab + HMA had a safety profile similar to that reported for HMA alone and demonstrated durable clinical responses in patients with HR/vHR-MDS. These results support the ongoing evaluation of sabatolimab-based combination therapy in MDS, CMML, and acute myeloid leukemia.
- Publisher
- Wiley
- Keywords
- Humans; Azacitidine/therapeutic use; Decitabine/therapeutic use; Antimetabolites, Antineoplastic/therapeutic use; *Myelodysplastic Syndromes/drug therapy; Hepatitis A Virus Cellular Receptor 2/therapeutic use; *Leukemia, Myelomonocytic, Chronic/drug therapy; *Leukemia, Myeloid, Acute/drug therapy; Antibodies/therapeutic use; Treatment Outcome; *Antibodies, Monoclonal
- Research Division(s)
- Blood Cells And Blood Cancer
- PubMed ID
- 37994196/
- Publisher's Version
- https://doi.org/10.1002/ajh.27161
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2023-11-30 09:13:25
Last Modified: 2024-01-25 09:16:18